Cargando...
Initial Experience With Tafamidis Treatment for Transthyretin Amyloid Cardiomyopathy
Background: Transthyretin amyloid cardiomyopathy is a progressive disease with a poor prognosis. There had been no specific treatment for transthyretin amyloid cardiomyopathy until tafamidis received expanded approval in March 2019 in Japan. However, the clinical efficacy of tafamidis remains unknow...
Gardado en:
| Publicado en: | Circ Rep |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
The Japanese Circulation Society
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7819654/ https://ncbi.nlm.nih.gov/pubmed/33693263 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1253/circrep.CR-20-0062 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|